Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO
Umme Sabrina Haque(University of Alberta), Toshifumi Yokota(University of Alberta), Melissa Kohut(University of Alberta)
Cited by 33
Related Papers
Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background
|Scientific Reports|2016|58
Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide
|Cells|2023|36
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
|Genes|2024|17
Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging Therapies
|Degenerative Neurological and Neuromuscular Disease|2025|9
Functional genomic analysis of K+ related salt-responsive transporters in tolerant and sensitive genotypes of rice
|Frontiers in Plant Science|2023|8